Why the study?
Does a single bolus injection of atrial natriuretic factor alter hemodynamics, renal function, and endocrine markers in healthy volunteers?
Does a single bolus injection of atrial natriuretic factor alter hemodynamics, renal function, and endocrine markers in healthy volunteers?
In healthy volunteers, intravenous bolus injections of atrial natriuretic factor produce significant hemodynamic and renal effects at a threshold dose of 100 μg, despite dose-dependent increases in cyclic GMP at lower doses.
Answers are grounded in this paper and cite their sources.
Threshold effects at 100 μg in volunteers merit patient studies; leaves open therapeutic utility in disease states.
The aim of this study was to examine the hemodynamic, renal, and endocrine effects of exogenous human atrial natriuretic factor (ANF), together with its pharmacokinetics, in healthy volunteers. Ten subjects participated in this study, in which the effects of a single bolus dose of ANF and of a matched vehicle injection were compared under a 135 mmol/day sodium intake. Doses of 3, 12.5, and 25 μg of ANF were given to 1 subject each, and doses of 50 and 100 μg were given to 4 and 3 subjects, respectively. Significantly, hemodynamic changes occurred at the 100 μg dose, when mean blood pressure decreased by 15% and heart rate increased reciprocally. Diuresis and natriuresis tended to increase following 50 μg but increased significantly and in a prolonged fashion following 100 μg of ANF. Atrial natriuretic factor did not cause significant changes in plasma catecholamine, renin activity, and aldosterone levels at any dose, although aldosterone tended to decrease. Plasma arginine-vasopressin concentrations decreased significantly following 100 μg. Plasma cyclic GMP levels increased in all subjects and in a dose-dependent fashion. Plasma ANF concentrations peaked 3-5 min following the bolus injection and returned toward baseline values within 10-60 min. Although with doses of ≤50 μg plasma ANF levels increased up to 8 to 50-fold, compared to baseline values, the only significant change was the increase in plasma cyclic GMP levels, perhaps because the effects of ANF were successfully masked by counter-regulatory mechanisms. Atrial natriuretic factor has a relatively large apparent volume of distribution averaging 30 ± 5 L and a short half-life of 4.7 ± 0.7 and 10.7 ± 3.8 min following 50 and 100 μg, respectively. In conclusion, when ANF was given as single intravenous bolus to healthy volunteers, the threshold dose for the blood pressure lowering effect of ANF was 100 μg, whereas the effect on plasma cyclic GMP levels was detectable following doses less than 25 μg. Similarly, there were no apparent inhibitory effects of ANF on plasma aldosterone and arginine-vasopressin levels with doses of less than 100 μg despite increases in plasma ANF levels up to 50-fold. Whether the acute release of endogenous ANF, which under physiological conditions increases its plasma level relatively modestly, has any hemodynamic, renal, or endocrine effects remains to be determined.
No takes yet. Share an insight, caveat, or question.
Cusson et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: